Metabolomics analyses reveal the crucial role of ERK in regulating metabolic pathways associated with the proliferation of human cutaneous T‐cell lymphoma cells treated with Glabridin

<p dir="ltr">Cutaneous T‐cell lymphomas (CTC) are a heterogeneous group of T‐cell lymphoproliferative malignancies of the skin with limited treatment options, increased resistance and remission. Metabolic reprogramming is vital in orchestrating the uncontrolled growth and proliferati...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلف الرئيسي: Abdul Q. Khan (14153247) (author)
مؤلفون آخرون: Maha Victor Agha (16932492) (author), Fareed Ahmad (134672) (author), Rasheeda Anver (17346850) (author), Khalid Sultan A. M. Sheikhan (21841388) (author), Jericha Mateo (21841391) (author), Majid Alam (14158959) (author), Joerg Buddenkotte (6293584) (author), Shahab Uddin (154400) (author), Martin Steinhoff (5340194) (author)
منشور في: 2024
الموضوعات:
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
_version_ 1864513543071596544
author Abdul Q. Khan (14153247)
author2 Maha Victor Agha (16932492)
Fareed Ahmad (134672)
Rasheeda Anver (17346850)
Khalid Sultan A. M. Sheikhan (21841388)
Jericha Mateo (21841391)
Majid Alam (14158959)
Joerg Buddenkotte (6293584)
Shahab Uddin (154400)
Martin Steinhoff (5340194)
author2_role author
author
author
author
author
author
author
author
author
author_facet Abdul Q. Khan (14153247)
Maha Victor Agha (16932492)
Fareed Ahmad (134672)
Rasheeda Anver (17346850)
Khalid Sultan A. M. Sheikhan (21841388)
Jericha Mateo (21841391)
Majid Alam (14158959)
Joerg Buddenkotte (6293584)
Shahab Uddin (154400)
Martin Steinhoff (5340194)
author_role author
dc.creator.none.fl_str_mv Abdul Q. Khan (14153247)
Maha Victor Agha (16932492)
Fareed Ahmad (134672)
Rasheeda Anver (17346850)
Khalid Sultan A. M. Sheikhan (21841388)
Jericha Mateo (21841391)
Majid Alam (14158959)
Joerg Buddenkotte (6293584)
Shahab Uddin (154400)
Martin Steinhoff (5340194)
dc.date.none.fl_str_mv 2024-06-30T09:00:00Z
dc.identifier.none.fl_str_mv 10.1111/cpr.13701
dc.relation.none.fl_str_mv https://figshare.com/articles/journal_contribution/Metabolomics_analyses_reveal_the_crucial_role_of_ERK_in_regulating_metabolic_pathways_associated_with_the_proliferation_of_human_cutaneous_T_cell_lymphoma_cells_treated_with_Glabridin/29714918
dc.rights.none.fl_str_mv CC BY 4.0
info:eu-repo/semantics/openAccess
dc.subject.none.fl_str_mv Biomedical and clinical sciences
Medical biochemistry and metabolomics
Oncology and carcinogenesis
Pharmacology and pharmaceutical sciences
Cancer biology
Metabolic reprogramming
Apoptosis
Autophagy
Necrosis
Drug sensitization
Bortezomib
Metabolomics
dc.title.none.fl_str_mv Metabolomics analyses reveal the crucial role of ERK in regulating metabolic pathways associated with the proliferation of human cutaneous T‐cell lymphoma cells treated with Glabridin
dc.type.none.fl_str_mv Text
Journal contribution
info:eu-repo/semantics/publishedVersion
text
contribution to journal
description <p dir="ltr">Cutaneous T‐cell lymphomas (CTC) are a heterogeneous group of T‐cell lymphoproliferative malignancies of the skin with limited treatment options, increased resistance and remission. Metabolic reprogramming is vital in orchestrating the uncontrolled growth and proliferation of cancer cells. Importantly, deregulated signalling plays a significant role in metabolic reprogramming. Considering the crucial role of metabolic reprogramming in cancer‐cell growth and proliferation, target identification and the development of novel and multi‐targeting agents are imperative. The present study explores the underlying mechanisms and metabolic signalling pathways associated with Glabridin mediated anti‐cancer actions in CTCL. Our results show that Glabridin significantly inhibits the growth of CTCL cells through induction of programmed cell death (PCD) such as apoptosis, autophagy and necrosis. Interestingly, results further show that Glabridin induces PCD in CTCL cells by targeting MAPK signalling pathways, particularly the activation of ERK. Further, Glabridin also sensitized CTCL cells to the anti‐cancer drug, bortezomib. Importantly, LC–MS‐based metabolomics analyses further showed that Glabridin targeted multiple metabolites and metabolic pathways intricately involved in cancer cell growth and proliferation in an ERK‐dependent fashion. Overall, our findings revealed that Glabridin induces PCD and attenuates the expression of regulatory proteins and metabolites involved in orchestrating the uncontrolled proliferation of CTCL cells through ERK activation. Therefore, Glabridin possesses important features of an ideal anti‐cancer agent.</p><h2>Other Information</h2><p dir="ltr">Published in: Cell Proliferation<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1111/cpr.13701" target="_blank">https://dx.doi.org/10.1111/cpr.13701</a></p>
eu_rights_str_mv openAccess
id Manara2_5e10fc29680c70a40e9c277ff58fbe55
identifier_str_mv 10.1111/cpr.13701
network_acronym_str Manara2
network_name_str Manara2
oai_identifier_str oai:figshare.com:article/29714918
publishDate 2024
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
rights_invalid_str_mv CC BY 4.0
spelling Metabolomics analyses reveal the crucial role of ERK in regulating metabolic pathways associated with the proliferation of human cutaneous T‐cell lymphoma cells treated with GlabridinAbdul Q. Khan (14153247)Maha Victor Agha (16932492)Fareed Ahmad (134672)Rasheeda Anver (17346850)Khalid Sultan A. M. Sheikhan (21841388)Jericha Mateo (21841391)Majid Alam (14158959)Joerg Buddenkotte (6293584)Shahab Uddin (154400)Martin Steinhoff (5340194)Biomedical and clinical sciencesMedical biochemistry and metabolomicsOncology and carcinogenesisPharmacology and pharmaceutical sciencesCancer biologyMetabolic reprogrammingApoptosisAutophagyNecrosisDrug sensitizationBortezomibMetabolomics<p dir="ltr">Cutaneous T‐cell lymphomas (CTC) are a heterogeneous group of T‐cell lymphoproliferative malignancies of the skin with limited treatment options, increased resistance and remission. Metabolic reprogramming is vital in orchestrating the uncontrolled growth and proliferation of cancer cells. Importantly, deregulated signalling plays a significant role in metabolic reprogramming. Considering the crucial role of metabolic reprogramming in cancer‐cell growth and proliferation, target identification and the development of novel and multi‐targeting agents are imperative. The present study explores the underlying mechanisms and metabolic signalling pathways associated with Glabridin mediated anti‐cancer actions in CTCL. Our results show that Glabridin significantly inhibits the growth of CTCL cells through induction of programmed cell death (PCD) such as apoptosis, autophagy and necrosis. Interestingly, results further show that Glabridin induces PCD in CTCL cells by targeting MAPK signalling pathways, particularly the activation of ERK. Further, Glabridin also sensitized CTCL cells to the anti‐cancer drug, bortezomib. Importantly, LC–MS‐based metabolomics analyses further showed that Glabridin targeted multiple metabolites and metabolic pathways intricately involved in cancer cell growth and proliferation in an ERK‐dependent fashion. Overall, our findings revealed that Glabridin induces PCD and attenuates the expression of regulatory proteins and metabolites involved in orchestrating the uncontrolled proliferation of CTCL cells through ERK activation. Therefore, Glabridin possesses important features of an ideal anti‐cancer agent.</p><h2>Other Information</h2><p dir="ltr">Published in: Cell Proliferation<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1111/cpr.13701" target="_blank">https://dx.doi.org/10.1111/cpr.13701</a></p>2024-06-30T09:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1111/cpr.13701https://figshare.com/articles/journal_contribution/Metabolomics_analyses_reveal_the_crucial_role_of_ERK_in_regulating_metabolic_pathways_associated_with_the_proliferation_of_human_cutaneous_T_cell_lymphoma_cells_treated_with_Glabridin/29714918CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/297149182024-06-30T09:00:00Z
spellingShingle Metabolomics analyses reveal the crucial role of ERK in regulating metabolic pathways associated with the proliferation of human cutaneous T‐cell lymphoma cells treated with Glabridin
Abdul Q. Khan (14153247)
Biomedical and clinical sciences
Medical biochemistry and metabolomics
Oncology and carcinogenesis
Pharmacology and pharmaceutical sciences
Cancer biology
Metabolic reprogramming
Apoptosis
Autophagy
Necrosis
Drug sensitization
Bortezomib
Metabolomics
status_str publishedVersion
title Metabolomics analyses reveal the crucial role of ERK in regulating metabolic pathways associated with the proliferation of human cutaneous T‐cell lymphoma cells treated with Glabridin
title_full Metabolomics analyses reveal the crucial role of ERK in regulating metabolic pathways associated with the proliferation of human cutaneous T‐cell lymphoma cells treated with Glabridin
title_fullStr Metabolomics analyses reveal the crucial role of ERK in regulating metabolic pathways associated with the proliferation of human cutaneous T‐cell lymphoma cells treated with Glabridin
title_full_unstemmed Metabolomics analyses reveal the crucial role of ERK in regulating metabolic pathways associated with the proliferation of human cutaneous T‐cell lymphoma cells treated with Glabridin
title_short Metabolomics analyses reveal the crucial role of ERK in regulating metabolic pathways associated with the proliferation of human cutaneous T‐cell lymphoma cells treated with Glabridin
title_sort Metabolomics analyses reveal the crucial role of ERK in regulating metabolic pathways associated with the proliferation of human cutaneous T‐cell lymphoma cells treated with Glabridin
topic Biomedical and clinical sciences
Medical biochemistry and metabolomics
Oncology and carcinogenesis
Pharmacology and pharmaceutical sciences
Cancer biology
Metabolic reprogramming
Apoptosis
Autophagy
Necrosis
Drug sensitization
Bortezomib
Metabolomics